Dexrazoxane Use in Pediatric Patients with Acute Lymphoblastic or Myeloid Leukemia From 1999 and 2009: Analysis of a National Cohort of Patients in the Pediatric Health Information Systems Database

BACKGROUND: Acute lymphoblastic (ALL) and myeloid leukemia (AML) account for approximately 26% of pediatric cancers. Anthracyclines are widely used to treat these leukemias, but dosing is limited by cardiotoxicity. Data support the efficacy of dexrazoxane as a cardioprotectant in children; however,...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Walker, Dana M., Fisher, Brian T., Seif, Alix E., Huang, Yuan-Shung V., Torp, Kari, Li, Yimei, Aplenc, Richard
Formato: Artigo
Idioma:Inglês
Publicado: 2012
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3918414/
https://ncbi.nlm.nih.gov/pubmed/22948886
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pbc.24270
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares